Current Research in Biotechnology最新文献_第5页

A study on the impact of electrode and membrane modification in stacked microbial fuel cells for wastewater treatment 电极和膜改性对堆垛式微生物燃料电池废水处理的影响研究

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-02-07 DOI: 10.1016/j.crbiot.2025.100278

Aritro Banerjee, Rajnish Kaur Calay, Somil Thakur, Mohamad Y. Mustafa

This study investigates the efficacy of treating wastewater using microbial fuel cell (MFC) technology to the safe limits for discharge in the environment. It has been demonstrated that MFC directly converts organic matter present in wastewater into energy. The present study uses a cell design based on simple plate geometry, carbon felt electrodes and Nafion117 as proton exchange membrane separating the anode and cathode chambers. The anode was then modified with heat and acid treatment and PEM was treated with PVDF to improve the performance of the cell. Synthetic dairy wastewater with initial COD of 2412 mg/l was used to test the operation of stack consisting of four cells which were hydraulically connected in series. The stack operated with continuous flow of wastewater. COD removal of the feed water was tested in successive cells to achieve the permissible limits for safe discharge of the effluent. COD decreased from 2412 mg/l to 126 mg/l after the fourth cell. For the power output each cell was treated individually. The power density of each cell was directly proportional to the COD of the influent. The power density of the first cell that has the highest COD was measured at 77.9 mW/m², which is two times that for the cell with unmodified anode and membrane. For the first cell COD removal was the highest at 57 % and 2.6 times more than the cell with the unmodified anode and membrane. These results suggest that targeted modifications to the anode and membrane can significantly boost the MFC performance both in terms of COD removal and corresponding power output. Secondly, up to 93.66 % COD removal may be achieved by four cells hydraulically connected in series. The paper offers some insights for stacking options for implementing at scale up of the MFC technology for wastewater treatment plants.

本研究探讨了微生物燃料电池（MFC）技术处理废水的效果，使其达到环境排放的安全限值。研究表明，MFC可直接将废水中的有机物转化为能源。本研究采用基于简单板几何的电池设计，碳毡电极和Nafion117作为质子交换膜分离阳极和阴极室。然后对阳极进行热处理和酸处理，对PEM进行PVDF处理，以提高电池的性能。以初始COD为2412 mg/l的乳业合成废水为试验材料，采用水力串联的4个池组成的反应器进行运行试验。这个烟囱是在污水不断流入的情况下运行的。在连续的单元中测试了对给水的COD去除，以达到安全排放出水的允许限度。COD由2412mg /l降至126mg /l。对于功率输出，每个单元被单独处理。各池的功率密度与进水COD成正比。COD最高的第一个电池的功率密度为77.9 mW/m2，是未修饰阳极和膜的电池的2倍。第一个电池的COD去除率最高，达到57%，是未修饰阳极和膜的2.6倍。这些结果表明，对阳极和膜进行针对性的修饰可以显著提高MFC的COD去除率和相应的功率输出。其次，采用液压串联4个电解槽，COD去除率可达93.66%。本文为污水处理厂大规模实施MFC技术的堆垛方案提供了一些见解。

{"title":"A study on the impact of electrode and membrane modification in stacked microbial fuel cells for wastewater treatment","authors":"Aritro Banerjee, Rajnish Kaur Calay, Somil Thakur, Mohamad Y. Mustafa","doi":"10.1016/j.crbiot.2025.100278","DOIUrl":"10.1016/j.crbiot.2025.100278","url":null,"abstract":"<div><div>This study investigates the efficacy of treating wastewater using microbial fuel cell (MFC) technology to the safe limits for discharge in the environment. It has been demonstrated that MFC directly converts organic matter present in wastewater into energy. The present study uses a cell design based on simple plate geometry, carbon felt electrodes and Nafion117 as proton exchange membrane separating the anode and cathode chambers. The anode was then modified with heat and acid treatment and PEM was treated with PVDF to improve the performance of the cell. Synthetic dairy wastewater with initial COD of 2412 mg/l was used to test the operation of stack consisting of four cells which were hydraulically connected in series. The stack operated with continuous flow of wastewater. COD removal of the feed water was tested in successive cells to achieve the permissible limits for safe discharge of the effluent. COD decreased from 2412 mg/l to 126 mg/l after the fourth cell. For the power output each cell was treated individually. The power density of each cell was directly proportional to the COD of the influent. The power density of the first cell that has the highest COD was measured at 77.9 mW/m<sup>2</sup>, which is two times that for the cell with unmodified anode and membrane. For the first cell COD removal was the highest at 57 % and 2.6 times more than the cell with the unmodified anode and membrane. These results suggest that targeted modifications to the anode and membrane can significantly boost the MFC performance both in terms of COD removal and corresponding power output. Secondly, up to 93.66 % COD removal may be achieved by four cells hydraulically connected in series. The paper offers some insights for stacking options for implementing at scale up of the MFC technology for wastewater treatment plants.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100278"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaporized hydrogen peroxide sterilization of powered air-purifying respirators: Efficacy and safety assessment 电动空气净化呼吸器的汽化过氧化氢灭菌：有效性和安全性评价

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-07-05 DOI: 10.1016/j.crbiot.2025.100312

Yeerzati Tuluhongtayi , Wenjun He , Kun Cai , Weifang Han , Sheng Zhang , Jun Liu , Wenwen Lei , Zongxing Zhang , Jiancheng Qi , Guizhen Wu

The COVID-19 pandemic increased demand for personal protective equipment, necessitating exploration of reprocessing methods. This study evaluates the efficacy and safety of vaporized hydrogen peroxide (VHP) sterilization for potential reuse of three powered air purifying respirator (PAPR) brands (3 M, Kebiao, Honeywell). Geobacillus stearothermophilus spores (ATCC 7953) served as biological indicators, while performance parameters (filtration, airflow, battery) and material integrity were monitored throughout 60 cycles, with H₂O₂ residual concentrations measured after 30 cycles. VHP achieved 100 % sterilization efficacy under both unloaded (48/48 biological indicators) and fully-loaded (132/132 biological indicators) conditions, demonstrating complete microbial inactivation across all sampling sites. However, brand-specific sterilization varied across operational conditions. 3 M units achieved complete sterilization in respiratory conduits when powered off but showed reduced filter efficacy. Kebiao units demonstrated complete sterilization when powered off but reduced efficacy during operation at internal filtration sites. Honeywell units with activated carbon showed poor VHP compatibility, while non-activated carbon units performed better when powered off. After 60 cycles, all PAPRs maintained filtration efficiency > 99.97 % and airflow rates > 120 L/min, with functional battery performance. H₂O₂ residual concentrations significantly exceeded safety thresholds (<1 ppm): 3.2 (2.0,4.6) ppm for 3 M, 6.1 (4.3,7.4) ppm for Kebiao, and 6.5 (4.1,8.2) ppm for Honeywell units, with 3 M showing significantly lower residuals (P < 0.05). This study provides critical evidence supporting VHP as a promising approach for PAPR sterilization. However, brand-specific protocols and extended ventilation procedures are required to ensure effective sterilization and reduce H₂O₂ residues to safe level.

COVID-19大流行增加了对个人防护装备的需求，有必要探索再加工方法。本研究评估了三个动力空气净化呼吸器（PAPR）品牌（3m，科标，霍尼韦尔）的潜在重复使用的汽化过氧化氢（VHP）灭菌的有效性和安全性。以嗜热硬脂嗜热地杆菌孢子（ATCC 7953）作为生物学指标，在60个循环中监测性能参数（过滤、气流、电池）和材料完整性，在30个循环后测量H2O2残留浓度。VHP在卸载（48/48生物指标）和满载（132/132生物指标）条件下均达到100%的灭菌效果，在所有采样点显示完全的微生物失活。然而，品牌特定的灭菌因操作条件而异。3 M单元在断电时实现了呼吸管道的完全消毒，但过滤效果降低。可标设备在断电时显示完全灭菌，但在内部过滤部位操作时效率降低。带有活性炭的霍尼韦尔单元显示出较差的VHP兼容性，而非活性炭单元在关闭电源时表现更好。经过60次循环后，所有papr均保持过滤效率；99.97%，气流率>；120l /min，具有功能性电池性能。H2O2残留浓度显著超过安全阈值（P <1 ppm）： 3m设备为3.2 (2.0,4.6)ppm，可标设备为6.1 (4.3,7.4)ppm，霍尼韦尔设备为6.5 (4.1,8.2)ppm， 3m设备的残留浓度显著低于安全阈值(P <；0.05)。这项研究提供了重要的证据，支持VHP作为PAPR灭菌的有前途的方法。然而，需要特定品牌的协议和延长的通风程序，以确保有效的灭菌和减少H2O2残留到安全水平。

{"title":"Vaporized hydrogen peroxide sterilization of powered air-purifying respirators: Efficacy and safety assessment","authors":"Yeerzati Tuluhongtayi , Wenjun He , Kun Cai , Weifang Han , Sheng Zhang , Jun Liu , Wenwen Lei , Zongxing Zhang , Jiancheng Qi , Guizhen Wu","doi":"10.1016/j.crbiot.2025.100312","DOIUrl":"10.1016/j.crbiot.2025.100312","url":null,"abstract":"<div><div>The COVID-19 pandemic increased demand for personal protective equipment, necessitating exploration of reprocessing methods. This study evaluates the efficacy and safety of vaporized hydrogen peroxide (VHP) sterilization for potential reuse of three powered air purifying respirator (PAPR) brands (3 M, Kebiao, Honeywell). <em>Geobacillus stearothermophilus</em> spores (ATCC 7953) served as biological indicators, while performance parameters (filtration, airflow, battery) and material integrity were monitored throughout 60 cycles, with H<sub>2</sub>O<sub>2</sub> residual concentrations measured after 30 cycles. VHP achieved 100 % sterilization efficacy under both unloaded (48/48 biological indicators) and fully-loaded (132/132 biological indicators) conditions, demonstrating complete microbial inactivation across all sampling sites. However, brand-specific sterilization varied across operational conditions. 3 M units achieved complete sterilization in respiratory conduits when powered off but showed reduced filter efficacy. Kebiao units demonstrated complete sterilization when powered off but reduced efficacy during operation at internal filtration sites. Honeywell units with activated carbon showed poor VHP compatibility, while non-activated carbon units performed better when powered off. After 60 cycles, all PAPRs maintained filtration efficiency > 99.97 % and airflow rates > 120 L/min, with functional battery performance. H<sub>2</sub>O<sub>2</sub> residual concentrations significantly exceeded safety thresholds (<1 ppm): 3.2 (2.0,4.6) ppm for 3 M, 6.1 (4.3,7.4) ppm for Kebiao, and 6.5 (4.1,8.2) ppm for Honeywell units, with 3 M showing significantly lower residuals (P < 0.05). This study provides critical evidence supporting VHP as a promising approach for PAPR sterilization. However, brand-specific protocols and extended ventilation procedures are required to ensure effective sterilization and reduce H<sub>2</sub>O<sub>2</sub> residues to safe level.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100312"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating biotechnology into diagnostic labs: Innovations in PCR and molecular procedures 将生物技术整合到诊断实验室：PCR和分子程序的创新

IF 4 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-08-06 DOI: 10.1016/j.crbiot.2025.100325

Muhammad Faran Tahir , Sidra Ishtiaq , Muhammad Anas , Ayesha Irfan , Mariusz Jaremko , Shah Fahad , Sezai Ercişli , Hanan Almahasheer , Nader R. Abdelsalam

The field of biotechnology has significantly contributed to progress in diagnostic laboratories, especially in the early identification of genetic disorders. Timely detection plays a vital role in the treatment and management of such conditions, and numerous molecular approaches have been established to identify disease markers with high accuracy and sensitivity. The polymerase chain reaction (PCR), a cornerstone technique in molecular biology, has seen various advancements, establishing it as an essential method in diagnostic settings for recognizing genetic abnormalities. PCR-based approaches have transformed the diagnostic process by amplifying trace amounts of DNA, allowing for the identification of mutations linked to a wide range of inherited conditions. This review explores the role of biotechnology in diagnostic labs, emphasizing genetic disease detection through molecular procedures. Special attention is given to innovations in PCR, highlighting new PCR-based techniques such as digital PCR, multiplex PCR, and reverse-transcription PCR, which have improved sensitivity and versatility. Additionally, various PCR methodologies, their diagnostic applications, and inherent limitations are discussed. The role of molecular tools in identifying diseases such as cancer, hereditary disorders, and infectious infections is also explored. The review further outlines the evolution of PCR technologies, their integration into molecular diagnostics, and their potential to improve diagnostic accuracy and enable early disease detection. Ongoing advancements in PCR technologies are transforming diagnostic practices by enabling more accurate, faster, and widely accessible molecular testing. These innovations promise enhanced disease management and better clinical outcomes, heralding a new era in healthcare.

生物技术领域极大地促进了诊断实验室的进展，特别是在遗传疾病的早期鉴定方面。及时发现在治疗和管理这些疾病中起着至关重要的作用，并且已经建立了许多分子方法来准确和敏感地识别疾病标志物。聚合酶链反应（PCR）是分子生物学的基础技术，已经取得了各种进展，使其成为识别遗传异常诊断环境中的基本方法。基于聚合酶链反应（pcr）的方法通过扩增微量DNA，从而改变了诊断过程，从而可以识别与多种遗传疾病相关的突变。这篇综述探讨了生物技术在诊断实验室中的作用，强调通过分子程序检测遗传病。特别关注PCR的创新，强调新的基于PCR的技术，如数字PCR，多重PCR和反转录PCR，这些技术提高了灵敏度和多功能性。此外，各种PCR方法，他们的诊断应用和固有的局限性进行了讨论。分子工具在识别疾病，如癌症，遗传性疾病和感染性感染的作用也进行了探讨。这篇综述进一步概述了PCR技术的发展，它们与分子诊断的结合，以及它们在提高诊断准确性和实现疾病早期检测方面的潜力。PCR技术的不断进步正在改变诊断实践，使分子检测更准确、更快速、更容易获得。这些创新承诺加强疾病管理和更好的临床结果，预示着医疗保健的新时代。

{"title":"Integrating biotechnology into diagnostic labs: Innovations in PCR and molecular procedures","authors":"Muhammad Faran Tahir , Sidra Ishtiaq , Muhammad Anas , Ayesha Irfan , Mariusz Jaremko , Shah Fahad , Sezai Ercişli , Hanan Almahasheer , Nader R. Abdelsalam","doi":"10.1016/j.crbiot.2025.100325","DOIUrl":"10.1016/j.crbiot.2025.100325","url":null,"abstract":"<div><div>The field of biotechnology has significantly contributed to progress in diagnostic laboratories, especially in the early identification of genetic disorders. Timely detection plays a vital role in the treatment and management of such conditions, and numerous molecular approaches have been established to identify disease markers with high accuracy and sensitivity. The polymerase chain reaction (PCR), a cornerstone technique in molecular biology, has seen various advancements, establishing it as an essential method in diagnostic settings for recognizing genetic abnormalities. PCR-based approaches have transformed the diagnostic process by amplifying trace amounts of DNA, allowing for the identification of mutations linked to a wide range of inherited conditions. This review explores the role of biotechnology in diagnostic labs, emphasizing genetic disease detection through molecular procedures. Special attention is given to innovations in PCR, highlighting new PCR-based techniques such as digital PCR, multiplex PCR, and reverse-transcription PCR, which have improved sensitivity and versatility. Additionally, various PCR methodologies, their diagnostic applications, and inherent limitations are discussed. The role of molecular tools in identifying diseases such as cancer, hereditary disorders, and infectious infections is also explored. The review further outlines the evolution of PCR technologies, their integration into molecular diagnostics, and their potential to improve diagnostic accuracy and enable early disease detection. Ongoing advancements in PCR technologies are transforming diagnostic practices by enabling more accurate, faster, and widely accessible molecular testing. These innovations promise enhanced disease management and better clinical outcomes, heralding a new era in healthcare.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100325"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the UCP1-dependent thermogenesis pathway with CRISPR/Cas9: a new approach to obesity management 利用CRISPR/Cas9靶向ucp1依赖性产热通路：肥胖管理的新途径

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-05-03 DOI: 10.1016/j.crbiot.2025.100295

Esmail Karami , Fatemeh Rostamkhani , Maasoume Abdollahi , Mohamadreza Ahmadifard

Obesity is a complex, multifactorial disease characterized by excessive body fat accumulation, which negatively impacts health. Its increasing prevalence has led to a global epidemic, emphasizing the urgent need for innovative and effective treatment strategies. This study aims to explore the potential of CRISPR/Cas9-mediated gene editing to enhance UCP1-dependent thermogenesis, offering a novel approach to obesity management. Uncoupling protein 1 (UCP1), primarily located in the inner mitochondrial membrane of brown adipose tissue (BAT), plays a crucial role in thermogenesis and energy expenditure. By converting stored energy into heat, UCP1 activation enhances calorie burning, helping to regulate body temperature and mitigate obesity-related health risks. Recent advancements in genome editing technologies, particularly CRISPR/Cas9, provide a precise method to modify genes involved in UCP1 expression and activity. This approach holds significant promise for sustainable obesity management by enhancing metabolic efficiency and energy expenditure. This study examines the feasibility of using CRISPR/Cas9 to target the UCP1-dependent thermogenesis pathway for obesity treatment. It explores the mechanisms of CRISPR/Cas9, the role of UCP1 in energy regulation, and potential strategies to enhance thermogenic activity. Our findings highlight the promise of CRISPR-based interventions in metabolic regulation. However, further research is necessary to optimize safety, efficacy, and regulatory considerations before translating these findings into clinical applications.

肥胖是一种复杂的多因素疾病，其特征是体内脂肪堆积过多，对健康产生负面影响。它的日益流行已导致全球流行病，强调迫切需要创新和有效的治疗战略。本研究旨在探索CRISPR/ cas9介导的基因编辑增强ucp1依赖性产热的潜力，为肥胖管理提供一种新的途径。解偶联蛋白1 （Uncoupling protein 1, UCP1）主要位于棕色脂肪组织（brown aditissue， BAT）的线粒体内膜内，在产热和能量消耗中起着至关重要的作用。通过将储存的能量转化为热量，UCP1的激活增强了卡路里的燃烧，有助于调节体温，减轻与肥胖相关的健康风险。基因组编辑技术的最新进展，特别是CRISPR/Cas9，提供了一种精确的方法来修饰参与UCP1表达和活性的基因。这种方法通过提高代谢效率和能量消耗，为可持续的肥胖管理带来了巨大的希望。本研究探讨了利用CRISPR/Cas9靶向ucp1依赖性产热通路治疗肥胖的可行性。它探讨了CRISPR/Cas9的机制，UCP1在能量调节中的作用，以及增强产热活性的潜在策略。我们的发现强调了基于crispr的代谢调节干预的前景。然而，在将这些发现转化为临床应用之前，还需要进一步的研究来优化安全性、有效性和监管方面的考虑。

{"title":"Targeting the UCP1-dependent thermogenesis pathway with CRISPR/Cas9: a new approach to obesity management","authors":"Esmail Karami , Fatemeh Rostamkhani , Maasoume Abdollahi , Mohamadreza Ahmadifard","doi":"10.1016/j.crbiot.2025.100295","DOIUrl":"10.1016/j.crbiot.2025.100295","url":null,"abstract":"<div><div>Obesity is a complex, multifactorial disease characterized by excessive body fat accumulation, which negatively impacts health. Its increasing prevalence has led to a global epidemic, emphasizing the urgent need for innovative and effective treatment strategies. This study aims to explore the potential of CRISPR/Cas9-mediated gene editing to enhance UCP1-dependent thermogenesis, offering a novel approach to obesity management. Uncoupling protein 1 (UCP1), primarily located in the inner mitochondrial membrane of brown adipose tissue (BAT), plays a crucial role in thermogenesis and energy expenditure. By converting stored energy into heat, UCP1 activation enhances calorie burning, helping to regulate body temperature and mitigate obesity-related health risks. Recent advancements in genome editing technologies, particularly CRISPR/Cas9, provide a precise method to modify genes involved in UCP1 expression and activity. This approach holds significant promise for sustainable obesity management by enhancing metabolic efficiency and energy expenditure. This study examines the feasibility of using CRISPR/Cas9 to target the UCP1-dependent thermogenesis pathway for obesity treatment. It explores the mechanisms of CRISPR/Cas9, the role of UCP1 in energy regulation, and potential strategies to enhance thermogenic activity. Our findings highlight the promise of CRISPR-based interventions in metabolic regulation. However, further research is necessary to optimize safety, efficacy, and regulatory considerations before translating these findings into clinical applications.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100295"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Marine-derived secondary metabolites in oncology: A comprehensive review 肿瘤中的海洋次生代谢物：综合综述

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-05-22 DOI: 10.1016/j.crbiot.2025.100300

Samah S. Abuzahrah , Serag Eldin I. Elbehairi , Tahani Bakhsh , Ahmed Atwa , Nouf Juaid , Reham Hassan Mekky

Marine-derived secondary metabolites are emerging as promising anticancer agents due to their structural diversity and potent bioactivity. Within the scope of this all-encompassing study, the most recent advancements in the identification, characterization, and therapeutic applications of marine-derived compounds in oncology are studied. In this review, we discuss various types of bioactive metabolites that are significant, such as macrolactins, polyketides, terpenes, and peptides that are derived from diverse marine organisms viz., bacteria, fungi, actinomycetes, microalgae, macroalgae, mangroves, sponges, coral reefs, mollusks, and echinodermata Unique compounds from marine organisms exhibit diverse mechanisms that selectively target cancer cells. This minimizes harm to healthy tissues and reduces side effects.“These metabolites interfere with key cancer progression pathways such as immune modulation, apoptosis, angiogenesis, metastasis, and cell cycle regulation. Additionally, they enhance conventional treatments like chemotherapy and immune therapy by overcoming drug resistance, particularly multidrug resistance (MDR) and the persistence of cancer stem cells (CSCs), major contributors to therapy failure. CSCs, characterized by self-renewal and therapy resistance, play a central role in tumor recurrence and drug resistance. This review highlights the novelty of marine metabolites, providing a comprehensive inventory of their clinical and commercial applications while emphasizing their role in advancing green medicine through sustainable drug discovery practices. This review shows the promise of marine-derived secondary metabolites in building the future of cancer therapies by incorporating insights from current studies. It also inspires further exploration of the development of these metabolites as clinically practicable treatments.

海洋次生代谢物由于其结构的多样性和强大的生物活性，正成为一种有前景的抗癌药物。在这个包罗万象的研究范围内，研究了海洋衍生化合物在肿瘤鉴定、表征和治疗应用方面的最新进展。在这篇综述中，我们讨论了各种重要的生物活性代谢物，如巨乳素、聚酮、萜烯和肽，它们来自不同的海洋生物，如细菌、真菌、放线菌、微藻、大藻、红树林、海绵、珊瑚礁、软体动物和棘皮动物。这样可以最大限度地减少对健康组织的伤害并减少副作用。“这些代谢物干扰关键的癌症进展途径，如免疫调节、细胞凋亡、血管生成、转移和细胞周期调节。此外，它们通过克服耐药性，特别是多药耐药（MDR）和癌症干细胞（CSCs）的持久性来增强化疗和免疫治疗等传统治疗，这是治疗失败的主要原因。CSCs具有自我更新和耐药的特点，在肿瘤复发和耐药中起核心作用。这篇综述强调了海洋代谢物的新颖性，提供了其临床和商业应用的全面清单，同时强调了它们在通过可持续的药物发现实践推进绿色医学方面的作用。这篇综述表明，通过结合当前研究的见解，海洋衍生的次级代谢物在建立癌症治疗的未来方面具有很大的前景。这也激发了进一步探索这些代谢物的发展作为临床可行的治疗方法。

{"title":"Marine-derived secondary metabolites in oncology: A comprehensive review","authors":"Samah S. Abuzahrah , Serag Eldin I. Elbehairi , Tahani Bakhsh , Ahmed Atwa , Nouf Juaid , Reham Hassan Mekky","doi":"10.1016/j.crbiot.2025.100300","DOIUrl":"10.1016/j.crbiot.2025.100300","url":null,"abstract":"<div><div>Marine-derived secondary metabolites are emerging as promising anticancer agents due to their structural diversity and potent bioactivity. Within the scope of this all-encompassing study, the most recent advancements in the identification, characterization, and therapeutic applications of marine-derived compounds in oncology are studied. In this review, we discuss various types of bioactive metabolites that are significant, such as macrolactins, polyketides, terpenes, and peptides that are derived from diverse marine organisms <em>viz</em>., bacteria, fungi, actinomycetes, microalgae, macroalgae, mangroves, sponges, coral reefs, mollusks, and echinodermata Unique compounds from marine organisms exhibit diverse mechanisms that selectively target cancer cells. This minimizes harm to healthy tissues and reduces side effects.“These metabolites interfere with key cancer progression pathways such as immune modulation, apoptosis, angiogenesis, metastasis, and cell cycle regulation. Additionally, they enhance conventional treatments like chemotherapy and immune therapy by overcoming drug resistance, particularly multidrug resistance (MDR) and the persistence of cancer stem cells (CSCs), major contributors to therapy failure. CSCs, characterized by self-renewal and therapy resistance, play a central role in tumor recurrence and drug resistance. This review highlights the novelty of marine metabolites, providing a comprehensive inventory of their clinical and commercial applications while emphasizing their role in advancing green medicine through sustainable drug discovery practices. This review shows the promise of marine-derived secondary metabolites in building the future of cancer therapies by incorporating insights from current studies. It also inspires further exploration of the development of these metabolites as clinically practicable treatments.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100300"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Workflow for evaluating enzyme immobilization and performance for continuous flow manufacturing 评估酶固定和连续流程生产性能的工作流程

IF 4 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-08-16 DOI: 10.1016/j.crbiot.2025.100327

Emily M. Luteran, Marc R. Aloisi, Wendi L. Akerley, Robert D. Gilbertson

Enzymes have shown promise in various industries due to their functional specificity, catalytic efficiency, and environmental sustainability. These biological catalysts can be a pivotal component of manufacturing pipelines like continuous flow chemistry. For this, there exists a need to robustly immobilize enzymes on solid supports and assess the effects of the solid supports on catalytic performance and stability. Here, we use an industrially relevant model enzyme, C. ensiformis (Jack bean) urease, to demonstrate immobilization and assess performance in the context of continuous flow manufacturing. Various immobilization strategies were screened focusing on immobilization efficiency, protocol simplicity, and urease biocatalyst kinetics. Based on this, CDI-agarose and NHS-agarose resins were identified as the best-performing immobilization strategies for urease. CDI-agarose-urease and NHS-agarose-urease were then scaled up and applied to a large-scale continuous flow reactor to evaluate product yields, operational stability, and long-term stability. These experiments identified differences in stability and performance depending on the immobilization method tested. This highlights the importance of screening immobilization methods and subsequent enzyme performance for each candidate biocatalyst used in manufacturing to promote optimal performance and stability. As such, this work provides a framework for evaluating enzyme biocatalyst immobilization approaches to improve performance and enable transition into industrial processes.

酶由于其功能特异性、催化效率和环境可持续性，在各个行业都显示出前景。这些生物催化剂可以成为制造管道的关键组成部分，如连续流化学。为此，有必要将酶固定在固体载体上，并评估固体载体对催化性能和稳定性的影响。在这里，我们使用一种工业上相关的模型酶，C. ensiformis（杰克豆）脲酶，来演示固定和评估在连续流制造背景下的性能。对不同的固定化策略进行了筛选，重点是固定化效率、方案简单性和脲酶生物催化剂动力学。基于此，cdi -琼脂糖和nhs -琼脂糖树脂被确定为脲酶的最佳固定策略。然后将cdi -琼脂糖脲酶和nhs -琼脂糖脲酶放大并应用于大型连续流反应器，以评估产品收率、操作稳定性和长期稳定性。这些实验确定了稳定性和性能的差异取决于所测试的固定方法。这突出了筛选固定方法和随后用于制造的每种候选生物催化剂的酶性能的重要性，以促进最佳性能和稳定性。因此，这项工作为评估酶生物催化剂固定化方法提供了一个框架，以提高性能并使其能够过渡到工业过程。

{"title":"Workflow for evaluating enzyme immobilization and performance for continuous flow manufacturing","authors":"Emily M. Luteran, Marc R. Aloisi, Wendi L. Akerley, Robert D. Gilbertson","doi":"10.1016/j.crbiot.2025.100327","DOIUrl":"10.1016/j.crbiot.2025.100327","url":null,"abstract":"<div><div>Enzymes have shown promise in various industries due to their functional specificity, catalytic efficiency, and environmental sustainability. These biological catalysts can be a pivotal component of manufacturing pipelines like continuous flow chemistry. For this, there exists a need to robustly immobilize enzymes on solid supports and assess the effects of the solid supports on catalytic performance and stability. Here, we use an industrially relevant model enzyme, <em>C. ensiformis</em> (Jack bean) urease, to demonstrate immobilization and assess performance in the context of continuous flow manufacturing. Various immobilization strategies were screened focusing on immobilization efficiency, protocol simplicity, and urease biocatalyst kinetics. Based on this, CDI-agarose and NHS-agarose resins were identified as the best-performing immobilization strategies for urease. CDI-agarose-urease and NHS-agarose-urease were then scaled up and applied to a large-scale continuous flow reactor to evaluate product yields, operational stability, and long-term stability. These experiments identified differences in stability and performance depending on the immobilization method tested. This highlights the importance of screening immobilization methods and subsequent enzyme performance for each candidate biocatalyst used in manufacturing to promote optimal performance and stability. As such, this work provides a framework for evaluating enzyme biocatalyst immobilization approaches to improve performance and enable transition into industrial processes.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100327"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144866518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing recombinant protein production by bacteria: strategies and challenges in heterologous systems 推进重组蛋白的细菌生产：策略和挑战在异源系统

IF 4 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-10-17 DOI: 10.1016/j.crbiot.2025.100342

Devtulya Chander , Diksha Koul , Arushe Tickoo , Asha Chaubey

Recombinant protein production in bacteria is pivotal in industrial biotechnology, which enables scalable, cost-effective, and efficient synthesis of therapeutic proteins and enzymes. Present review explores key bacterial hosts including Escherichia coli, Bacillus subtilis, Bacillus licheniformis, and Brevibacillus choshinensis and more with an emphasis on extracellular heterologous protein production. Herein,we focus on secretion pathways such as Sec, Twin-arginine translocation (Tat) pathway, and ATP Binding Cassette (ABC) transporter systems, which govern protein export across membranes. The molecular strategies ranging from promoter optimization and codon adaptation to signal peptide engineering, strain modification, as well as protein fusion techniques have been highlighted that lead to improved secretion efficiency and product yields. Comparative insights into Gram-positive and Gram-negative systems, along with case studies, as well as importance of tailored approaches for different hosts and proteins have been reviewed. The review further discusses the growing relevance of CRISPR/Cas9n-based genetic interventions and the role of microbial physiology in facilitating optimized protein folding and transport. Overall, the integration of synthetic biology, secretion engineering, and host optimization offers promising avenues for advancing the extracellular production of high-value recombinant proteins.

在细菌中生产重组蛋白是工业生物技术的关键，它使治疗蛋白和酶的合成具有可扩展性、成本效益和效率。本文综述了大肠杆菌、枯草芽孢杆菌、地衣芽孢杆菌和短芽孢杆菌等主要寄主，重点介绍了细胞外异源蛋白的生产。在此，我们重点关注分泌途径，如Sec、双精氨酸易位（Tat）途径和ATP结合盒（ABC）转运体系统，它们控制蛋白质跨膜输出。从启动子优化和密码子适应到信号肽工程、菌株修饰以及蛋白质融合技术的分子策略已经得到强调，从而提高了分泌效率和产物产量。本文综述了革兰氏阳性和革兰氏阴性系统的比较见解，以及案例研究，以及针对不同宿主和蛋白质量身定制方法的重要性。这篇综述进一步讨论了基于CRISPR/ cas9n的遗传干预的日益增长的相关性以及微生物生理学在促进优化蛋白质折叠和运输中的作用。总之，合成生物学、分泌工程和宿主优化的整合为推进高价值重组蛋白的细胞外生产提供了有希望的途径。

{"title":"Advancing recombinant protein production by bacteria: strategies and challenges in heterologous systems","authors":"Devtulya Chander , Diksha Koul , Arushe Tickoo , Asha Chaubey","doi":"10.1016/j.crbiot.2025.100342","DOIUrl":"10.1016/j.crbiot.2025.100342","url":null,"abstract":"<div><div>Recombinant protein production in bacteria is pivotal in industrial biotechnology, which enables scalable, cost-effective, and efficient synthesis of therapeutic proteins and enzymes. Present review explores key bacterial hosts including <em>Escherichia coli</em>, <em>Bacillus subtilis</em>, <em>Bacillus licheniformis</em>, and <em>Brevibacillus choshinensis</em> and more with an emphasis on extracellular heterologous protein production. Herein,we focus on secretion pathways such as Sec, Twin-arginine translocation (Tat) pathway, and ATP Binding Cassette (ABC) transporter systems, which govern protein export across membranes. The molecular strategies ranging from promoter optimization and codon adaptation to signal peptide engineering, strain modification, as well as protein fusion techniques have been highlighted that lead to improved secretion efficiency and product yields. Comparative insights into Gram-positive and Gram-negative systems, along with case studies, as well as importance of tailored approaches for different hosts and proteins have been reviewed. The review further discusses the growing relevance of CRISPR/Cas9n-based genetic interventions and the role of microbial physiology in facilitating optimized protein folding and transport. Overall, the integration of synthetic biology, secretion engineering, and host optimization offers promising avenues for advancing the extracellular production of high-value recombinant proteins.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100342"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145415383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the innovation landscape of ginger: Insights from patent documentation analysis 探索生姜的创新前景：来自专利文件分析的见解

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-05-11 DOI: 10.1016/j.crbiot.2025.100299

Maima Matin , Bhupinder Kapoor , Monica Gulati , Michel-Edwar Mickael , Farhan Bin Matin , Agnieszka Kamińska , Joanna Bensz , Dariusz Sołdacki , Agnieszka Wierzbicka , Monika Marcinkowska-Lesiak , Ahmed Fatimi , Hong-Yan Liu , Ren-You Gan , Olga Adamska , Artur Stolarczyk , Jarosław Olav Horbańczuk , Artur Jóźwik , Atanas G. Atanasov

Zingiber officinale, commonly known as ginger, holds a prominent place in both culinary and medicinal practices worldwide. This study is the first to present a comprehensive analysis of ginger-related patents, aiming to elucidate patterns and trends in innovation surrounding this versatile plant. The analysis, conducted using The Lens database, encompasses 7193 patent documents retrieved on April 26, 2025. Annual patent counts illustrate a significant increase in ginger-related patents over the years, with a notable rise observed since 2010. Analysis of the Cooperative Patent Classification system provides a structured framework for organizing these patents, revealing predominant covered categories such as food compositions, plant extracts, and tea substitutes. Additionally, the top-cited patents underscore the diverse applications of ginger, ranging from therapeutic formulations to food and beverage additives. Furthermore, examination of frequently mentioned diseases in ginger patents identifies respiratory ailments, digestive disorders, and skin conditions as key therapeutic areas. These findings show the multifaceted nature of ginger’s pharmacological properties and its potential in addressing various health challenges. Overall, by focusing on ginger as a key food and medicine plant, this study highlights the significance of patent analysis in understanding the innovation landscape of medicinal plants and nutraceuticals, and is specifically opening the ways for future research and development in ginger utilization for global health promotion and sustainable development.

姜，俗称姜，在世界各地的烹饪和医学实践中都占有重要地位。本研究首次对生姜相关专利进行了全面分析，旨在阐明围绕这种多功能植物的创新模式和趋势。该分析是使用The Lens数据库进行的，包含了2025年4月26日检索到的7193份专利文件。年度专利数量表明，多年来与生姜相关的专利数量显著增加，自2010年以来出现了显著增长。对合作专利分类系统的分析为组织这些专利提供了一个结构化的框架，揭示了主要涵盖的类别，如食品成分、植物提取物和茶叶替代品。此外，被引用最多的专利强调了生姜的多种应用，从治疗配方到食品和饮料添加剂。此外，对生姜专利中经常提到的疾病进行检查，发现呼吸系统疾病、消化系统疾病和皮肤疾病是关键的治疗领域。这些发现显示了生姜药理特性的多面性及其在解决各种健康挑战方面的潜力。总体而言，本研究以生姜为重点食药植物，突出了专利分析对了解药用植物和保健品创新格局的重要意义，为未来生姜利用的研究开发开辟了道路，促进全球健康和可持续发展。

{"title":"Exploring the innovation landscape of ginger: Insights from patent documentation analysis","authors":"Maima Matin , Bhupinder Kapoor , Monica Gulati , Michel-Edwar Mickael , Farhan Bin Matin , Agnieszka Kamińska , Joanna Bensz , Dariusz Sołdacki , Agnieszka Wierzbicka , Monika Marcinkowska-Lesiak , Ahmed Fatimi , Hong-Yan Liu , Ren-You Gan , Olga Adamska , Artur Stolarczyk , Jarosław Olav Horbańczuk , Artur Jóźwik , Atanas G. Atanasov","doi":"10.1016/j.crbiot.2025.100299","DOIUrl":"10.1016/j.crbiot.2025.100299","url":null,"abstract":"<div><div><em>Zingiber officinale</em>, commonly known as ginger, holds a prominent place in both culinary and medicinal practices worldwide. This study is the first to present a comprehensive analysis of ginger-related patents, aiming to elucidate patterns and trends in innovation surrounding this versatile plant. The analysis, conducted using The Lens database, encompasses 7193 patent documents retrieved on April 26, 2025. Annual patent counts illustrate a significant increase in ginger-related patents over the years, with a notable rise observed since 2010. Analysis of the Cooperative Patent Classification system provides a structured framework for organizing these patents, revealing predominant covered categories such as food compositions, plant extracts, and tea substitutes. Additionally, the top-cited patents underscore the diverse applications of ginger, ranging from therapeutic formulations to food and beverage additives. Furthermore, examination of frequently mentioned diseases in ginger patents identifies respiratory ailments, digestive disorders, and skin conditions as key therapeutic areas. These findings show the multifaceted nature of ginger’s pharmacological properties and its potential in addressing various health challenges. Overall, by focusing on ginger as a key food and medicine plant, this study highlights the significance of patent analysis in understanding the innovation landscape of medicinal plants and nutraceuticals, and is specifically opening the ways for future research and development in ginger utilization for global health promotion and sustainable development.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100299"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Edible domestic animal blood products for biomedical and disease treatment applications 用于生物医学和疾病治疗的食用家畜血液制品

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-06-24 DOI: 10.1016/j.crbiot.2025.100308

Zhi Cao , Imran Mahmood Khan , Xiangrui Niu , Yang Hu , Zhuang Duan , Qiang Fang , Zhouping Wang , Junsong Yang

Edible blood products from domestic livestock are high-value derivatives produced during slaughter, with significant potential in biomedicine and disease treatment. Livestock blood is rich in proteins, peptides, iron, vitamins and other bioactive substances. Among them, functional proteins and peptides have been widely studied for their prominent roles in drug delivery, immune regulation, anti-infection and antioxidation. They significantly impact cancer treatment and immune regulation, providing valuable resources for innovation in the food and pharmaceutical industries. The development and utilization of livestock blood products offer innovative solutions for disease treatment and promote the sustainable development of the food and pharmaceutical industries by reducing the environmental burden of blood waste. However, challenges such as the complexity of blood composition, the variability of bioactive compound effectiveness, and the need for advanced purification techniques limit their broader applications. Additionally, regulatory and safety concerns must be addressed for therapeutic suitability. This review highlights the recent advancements in the biomedical applications of livestock blood products in biomedicine, addressing these challenges and emphasizing their potential to reduce environmental waste and promote sustainable development. This review consolidates current knowledge to provide a foundation for future research, fostering innovation in disease intervention and therapy while addressing utilization barriers.

家畜食用血制品是屠宰过程中产生的高价值衍生物，在生物医学和疾病治疗方面具有巨大潜力。家畜血液中含有丰富的蛋白质、多肽、铁、维生素等生物活性物质。其中功能蛋白和肽因其在药物传递、免疫调节、抗感染和抗氧化等方面的突出作用而受到广泛研究。它们显著影响癌症治疗和免疫调节，为食品和制药行业的创新提供宝贵的资源。牲畜血液制品的开发和利用为疾病治疗提供了创新的解决方案，并通过减少血液废物的环境负担来促进食品和制药行业的可持续发展。然而，诸如血液成分的复杂性、生物活性化合物有效性的可变性以及对先进纯化技术的需求等挑战限制了它们的广泛应用。此外，必须解决治疗适宜性的监管和安全问题。本文综述了家畜血液制品在生物医学中的生物医学应用的最新进展，解决了这些挑战，并强调了它们在减少环境浪费和促进可持续发展方面的潜力。这篇综述巩固了现有的知识，为未来的研究提供了基础，促进了疾病干预和治疗的创新，同时解决了利用障碍。

{"title":"Edible domestic animal blood products for biomedical and disease treatment applications","authors":"Zhi Cao , Imran Mahmood Khan , Xiangrui Niu , Yang Hu , Zhuang Duan , Qiang Fang , Zhouping Wang , Junsong Yang","doi":"10.1016/j.crbiot.2025.100308","DOIUrl":"10.1016/j.crbiot.2025.100308","url":null,"abstract":"<div><div>Edible blood products from domestic livestock are high-value derivatives produced during slaughter, with significant potential in biomedicine and disease treatment. Livestock blood is rich in proteins, peptides, iron, vitamins and other bioactive substances. Among them, functional proteins and peptides have been widely studied for their prominent roles in drug delivery, immune regulation, anti-infection and antioxidation. They significantly impact cancer treatment and immune regulation, providing valuable resources for innovation in the food and pharmaceutical industries. The development and utilization of livestock blood products offer innovative solutions for disease treatment and promote the sustainable development of the food and pharmaceutical industries by reducing the environmental burden of blood waste. However, challenges such as the complexity of blood composition, the variability of bioactive compound effectiveness, and the need for advanced purification techniques limit their broader applications. Additionally, regulatory and safety concerns must be addressed for therapeutic suitability. This review highlights the recent advancements in the biomedical applications of livestock blood products in biomedicine, addressing these challenges and emphasizing their potential to reduce environmental waste and promote sustainable development. This review consolidates current knowledge to provide a foundation for future research, fostering innovation in disease intervention and therapy while addressing utilization barriers.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100308"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144492004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The immunomodulatory effects of chito-oligosaccharides derived from Alcaligenes faecalis chitinase on cyclophosphamide-induced immunosuppression in mice 粪碱性几丁质酶壳寡糖对环磷酰胺诱导小鼠免疫抑制的免疫调节作用

IF 4 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Current Research in Biotechnology

Pub Date : 2025-01-01 Epub Date: 2025-10-11 DOI: 10.1016/j.crbiot.2025.100343

Rajesh K.M. , Anusha Govindula , Madhura M. Bose , Jayesh Mudgal , Ritu Raval

This study explores the immunomodulatory effects of chito-oligosaccharides (COS) derived from Alcaligenes faecalis chitinase in a cyclophosphamide-induced immunosuppression model in Swiss albino male mice. Mice received cyclophosphamide (80 mg/kg, i.p.) to induce immunosuppression, followed by oral administration of enzymatically derived COS (E-COS) and chemically synthesized COS (C-COS) at 20 mg/kg/day for 15 days. Both E-COS and C-COS significantly increased WBC (4.50 ± 0.71 and 5.37 ± 0.91) and RBC (5.80 ± 0.83 and 5.74 ± 0.86) counts compared to the cyclophosphamide group (1.43 ± 0.49 and 2.54 ± 0.76). Histopathological analysis showed thymic architecture restoration and reduced splenic lymphocyte apoptosis. Additionally, COS treatment elevated proinflammatory cytokine levels (TNF-α, IL-6, IL-1β) and decreased oxidative stress markers (malondialdehyde, glutathione). These findings suggest that COS possess immunomodulatory potential and may counteract cyclophosphamide-induced immunosuppression.

本研究探讨了粪Alcaligenes几丁质酶提取的壳寡糖（COS）在环磷酰胺诱导的瑞士白化雄性小鼠免疫抑制模型中的免疫调节作用。小鼠口服环磷酰胺（80 mg/kg, ig）诱导免疫抑制，然后分别口服酶促COS （E-COS）和化学合成COS (C-COS)，剂量为20 mg/kg/d，连续15 d。与环磷酰胺组（1.43±0.49和2.54±0.76）相比，E-COS和C-COS均显著增加WBC（4.50±0.71和5.37±0.91）和RBC（5.80±0.83和5.74±0.86）计数。组织病理学分析显示胸腺结构恢复，脾脏淋巴细胞凋亡减少。此外，COS处理可提高促炎细胞因子（TNF-α、IL-6、IL-1β）水平，降低氧化应激标志物（丙二醛、谷胱甘肽）。这些发现提示COS具有免疫调节潜能，可能抵消环磷酰胺诱导的免疫抑制。

{"title":"The immunomodulatory effects of chito-oligosaccharides derived from Alcaligenes faecalis chitinase on cyclophosphamide-induced immunosuppression in mice","authors":"Rajesh K.M. , Anusha Govindula , Madhura M. Bose , Jayesh Mudgal , Ritu Raval","doi":"10.1016/j.crbiot.2025.100343","DOIUrl":"10.1016/j.crbiot.2025.100343","url":null,"abstract":"<div><div>This study explores the immunomodulatory effects of chito-oligosaccharides (COS) derived from <em>Alcaligenes faecalis</em> chitinase in a cyclophosphamide-induced immunosuppression model in Swiss albino male mice. Mice received cyclophosphamide (80 mg/kg, i.p.) to induce immunosuppression, followed by oral administration of enzymatically derived COS (E-COS) and chemically synthesized COS (C-COS) at 20 mg/kg/day for 15 days. Both E-COS and C-COS significantly increased WBC (4.50 ± 0.71 and 5.37 ± 0.91) and RBC (5.80 ± 0.83 and 5.74 ± 0.86) counts compared to the cyclophosphamide group (1.43 ± 0.49 and 2.54 ± 0.76). Histopathological analysis showed thymic architecture restoration and reduced splenic lymphocyte apoptosis. Additionally, COS treatment elevated proinflammatory cytokine levels (TNF-α, IL-6, IL-1β) and decreased oxidative stress markers (malondialdehyde, glutathione). These findings suggest that COS possess immunomodulatory potential and may counteract cyclophosphamide-induced immunosuppression.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"10 ","pages":"Article 100343"},"PeriodicalIF":4.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145319559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0